Treating disorders mediated by vascular smooth muscle cell proli

Details Treating disorders mediated by vascular smooth muscle cell proli Treating disorders mediated by vascular smooth muscle cell proli

1995-10-27

1996-11-12

Henley, III, Raymond

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

A61K 31415

Patent

active

055740596

ABSTRACT:
Disorders mediated by vascular smooth muscle proliferation are treated by administering a vascular smooth muscle antiproliferative effective amount of an I.sub.2 imidazoline receptor agonist. The disorders include atherosclerosis, risk of blockage of artery after coronary angioplasty or blood vessel injury from non-angioplasty cause, and proliferative diabetic retinopathy. I.sub.2 imidazoline receptor agonists include idazoxan, UK 14,304, naphazoline, cirazoline and agmatine.

REFERENCES:
patent: 4507321 (1985-03-01), Raisfeld
patent: 4818764 (1989-04-01), Chapleo et al.
patent: 5059624 (1991-10-01), Monache et al.
patent: 5344846 (1994-09-01), Jakus et al.
Jackson, C. L., et al, Hypertension 20, 713-716 (1992).
Nakaki, T., et al, Molecular Pharmacology 37, 30-36 (1989).
Regunathan, S., et al, Annals of the New York Academy of Sciences, vol. 763, 580-590 (Jul. 1995).

Affiliated with

Also associated with

Rating

Treating disorders mediated by vascular smooth muscle cell proli does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Treating disorders mediated by vascular smooth muscle cell proli, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treating disorders mediated by vascular smooth muscle cell proli will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-562935